PuSH - Publication Server of Helmholtz Zentrum München: Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Lehrke, M.* ; Becker, A.* ; Greif, M.* ; Stark, R.G. ; Laubender, R.P. ; von Ziegler, F.* ; Lebherz, C.* ; Tittus, J.* ; Reiser, M.* ; Becker, C. ; Göke, B.* ; Leber, A.W.* ; Parhofer, K.G.* ; Broedl, U.C.*

Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis.

Eur. J. Endocrinol. 161, 339-344 (2009)

DOI

PMC

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

Objectives: Chemerin is a recently discovered adipokine that regulates adipocyte differentiation and modulates chemotaxis and activation of dendritic cells and macrophages. Given the convergence of adipocyte and macrophage function, chemerin may provide an interesting link between obesity, inflammation and atherosclerosis in humans. We sought to examine the relationship of 1) chemerin and markers of inflammation, 2) chemerin and components of the metabolic syndrome, and 3) chemerin and coronary atherosclerotic plaque burden and morphology. Design: Serum chemerin levels were determined in 303 patients with stable typical or atypical chest pain who underwent dual-source multi-slice CT-angiography to exclude coronary artery stenosis. Atherosclerotic plaques were classified as calcified, mixed or non-calcified. Results: Chemerin levels were highly correlated with hsCRP (r=0.44, p<0.0001), IL-6 (r=0.18, p=0.002), TNF-{alpha} (r=0.24, p<0.0001), resistin (r=0.28, p<0.0001) and leptin (r=0.36, p<0.0001) concentrations. Furthermore, chemerin was associated with components of the metabolic syndrome including BMI (r=0.23, p=0.0002), triglycerides (r=0.29, p<0.0001), HDL-C (r=-0.18, p=0.003) and hypertension (p<0.0001). In bivariate analysis, chemerin levels weakly correlated with coronary plaque burden (r=0.16, p=0.006) and the number of non-calcified plaques (r=0.14, p=0.02). These associations, however, were lost after adjusting for established cardiovascular risk factors (OR 1.17, 95%CI 0.97 to 1.41, p=0.11 for coronary plaque burden; OR 1.06, 95%CI 0.96 to 1.17, p=0.22 for non-calcified plaques). Conclusions: Chemerin is strongly associated with markers of inflammation and components of the metabolic syndrome. Chemerin, however, does not predict coronary atherosclerosis.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

3.791

1.520

167

249